Neuropathy

Home Page
Acne
Actinic Keratosis
Alcoholism
Alopecia areata
Andropause
Angioma
Aquagenic Pruritus
Asthma
Athlete's Foot
Atopic Dermatitis
Baldness
Baldness Treatments
Basal Cell Carcinoma
Bedsores
Behcet's Disease
Blepharitis
Boils
Bowen's Disease
Bullous Pemphigoid
Canker Sores
Carbuncles
Cellulite
Cellulitis
Cercarial Dermatitis
Cerebral Palsy
Cold Sores
Dandruff
Dermatitis Herpetiformis
Dermatofibroma
Dermatology
Domestic Violence
Dyshidrosis
Emphysema
Erectile Dysfunction
Menopause
Neuropathy
Personal Injury
Seborrhoeic Dermatitis
Spousal Abuse
Tooth Bleaching
Trichotillomania
Urology
Varicose veins

Neuropathy

Neuropathy, strictly speaking, is any disease that affects the nervous system. In common usage, however, neuropathy is short for peripheral neuropathy, meaning a disease of the peripheral nervous system, or in other words, a disease affecting one or more nerves.

Contents

Types

The four major forms of nerve damage are polyneuropathy, autonomic neuropathy, mononeuropathy, and mononeuritis multiplex. The most common form is peripheral polyneuropathy, which mainly affects the feet and legs.

Causes

Besides diabetes, the common causes of neuropathy are herpes zoster infection, chronic trauma (such as repetitive motion disorders) or acute trauma (including surgery), and various neurotoxins. Neuropathic pain is common in cancer as a direct result of the cancer on peripheral nerves (e.g., compression by a tumor), as a side effect of many chemotherapy drugs, and as a result of electrical injury. In many cases no apparent causes can be found, in this case the neuropathy is "idiopathic" meaning no cause is found.

Symptoms

Neuropathy often results in numbness, abnormal sensations called dysesthesias and allodynias that occur either spontaneously or in reaction to external stimuli, and a characteristic form of pain, called neuropathic pain or neuralgia, that is qualitatively different from the ordinary nociceptive pain one might experience from stubbing a toe or hitting a finger with a hammer. Neuropathic pain is usually perceived as a steady burning and/or "pins and needles" and/or "electric shock" sensations. The difference is due to the fact that "ordinary" pain stimulates only pain nerves, while a neuropathy often results in the firing of both pain and non-pain (touch, warm, cool) sensory nerves in the same area, producing signals that the spinal cord and brain do not normally expect to receive.

Treatment of Neuropathic Pain

Neuropathic pain can be very difficult to treat; sometimes strong opioid analgesics may provide only partial relief. Opoid analgesics are to be considered only as a tertiary treatment. Several classes of medications not normally thought of as analgesics are often effective, alone or in combination with opioids and other treatments. These include tricyclic antidepressants such as amitriptyline (Elavil®), anticonvulsants such as gabapentin (Neurontin®) and pregabalin (Lyrica®) and serotonin norepinephrine reuptake inhibitors (SSNRI such as duloxetine (Cymbalta®)).

In animal models of neuropathic pain (Bennett & Xie, Pain 33, 87-107 (1988); Seltzer et al., Pain 43, 205-18 (1990); Kim & Chung, Pain 50, 355-63 (1992); Malmberg & Basbaum, Pain 76, 215-22 (1998); Sung et al., Neurosci Lett 246, 117-9 (1998) ; Lee et al., Neuroreport 11, 657-61 (2000); Decosterd & Woolf, Pain 87, 149-58 (2000); Vadakkan et al., J Pain 6, 747-56 (2005), compounds that only block serotonin reuptake do not improve neuropathic pain. Similarly, compounds that only block norepinephrine reuptake also do not improve neuropathic pain. Compounds such as dulexetine, venlafaxine, and milnacipran that block both serotonin reuptake and norepinephrine reuptake do improve neuropathic pain. Antidepressants usually reduce neuropathic pain more quickly and with smaller doses than they relieve depression. Antidepressants therefore seem to work differently on neuropathic pain than on depression, perhaps by activating descending norepinephrinergic and serotonergic pathways in the spinal cord that block pain signals from ascending to the brain.

The newer anticonvulsants gabapentin and pregabalin appear to work by blocking calcium channels in damaged peripheral neurons. Tricyclic antidepressants may also work on sodium channels in peripheral nerves. The anticonvulsants carbamazepine (Tegretol®) and oxcarbazepine (Trileptal®), especially effective on trigeminal neuralgia, are thought to work principally on sodium channels.

In general, the antidepressants seem to be most effective on continuous burning pain, while the anticonvulsants seem to work best on sudden, lancinating, "shock-like" pains that appear to involve large numbers of peripheral nerves improperly firing together.

In some forms of neuropathy, especially post-herpes neuralgia, the topical application of local anesthetics such as lidocaine can provide relief. A transdermal patch containing 5% lidocaine is available. Ketamine in a transdermal gel is also frequently effective when the neuropathy is localized. Neurontin 100mg/g PLO gel is also effective for treating peripheral neuropathy, including Carpal Tunnel Syndrome.

In some neuropathic pain syndromes, "crosstalk" occurs between descending sympathetic nerves and ascending sensory nerves. Increases in sympathetic nervous system activity result in an increase of pain; this is known as sympathetically-mediated pain. Reducing the sympathetic nerve activity in the painful region with local nerve blocks or systemic medications such as clonidine may provide relief.

The NMDA receptor seems to play a major role in neuropathic pain and in the development of opioid tolerance, and many experiments in both animals and humans have established that NMDA antagonists such as ketamine and dextromethorphan can alleviate neuropathic pain and reverse opioid tolerance. Unfortunately, only a few NMDA antagonists are clinically available and their use is usually associated with unacceptable side effects.

Several opioids, particularly methadone, have NMDA antagonist activity in addition to their µ-opioid agonist properties that seems to make them effective against neuropathic pain, although this is still the subject of intensive research and clinical study. Methadone has this property because it is a racemic mixture; one stereo-isomer is a µ-opioid agonist; the other is a NMDA antagonist.

In addition to pharmacological treatment there are several other modalities that help some cases. While lacking double blind trials, these have shown to reduce pain and improve patient quality of life particularly for chronic neuropathic pain: Interferential Stimulation; Acupuncture; Meditation; Cognitive Therapy; and prescribed exercise.

This article (or parts thereof) is copied from an article on Wikipedia.org - the free encyclopedia created and edited by online user community. Although the vast majority of the wikipedia encyclopedia articles provide accurate and timely information please do not assume the accuracy of any particular article. This article is distributed under the terms of GNU Free Documentation License.

Articles:

Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S (News-Medical-Net)
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of diabetic neuropathy, a drug that has disease-modifying potential would earn 40 percent patient share in the U.S., according to surveyed U.S. neurologists. Similarly, in Europe, such a drug would earn a comparable patient share of 43 percent ...
Wed, 24 Feb 2010 11:48:14 GMT

Allon Presents Peripheral Neuropathy Preclinical Efficacy Data For AL-309 (Marketwire)
TOKYO, JAPAN--(Marketwire - Feb. 23, 2010) - Allon Therapeutics Inc . (TSX:NPC) today announced preclinical data demonstrating the potential of AL-309 , the Company's early-stage drug candidate. AL-309 is being investigated as a treatment for peripheral neuropathy, a debilitating and painful disorder of the peripheral nervous system afflicting millions of people for which there is no effective ...
Tue, 23 Feb 2010 14:11:32 GMT

Allon Presents Peripheral Neuropathy Preclinical Efficacy Data For AL-309 (CCNMatthews via Yahoo! Finance)
TOKYO, JAPAN-- - Allon Therapeutics Inc. today announced preclinical data demonstrating the potential of AL-309, the Company's early-stage drug candidate. AL-309 is being investigated as a treatment for peripheral neuropathy, a debilitating and painful disorder of the peripheral nervous system afflicting millions of people for which there is no effective treatment.
Tue, 23 Feb 2010 14:01:16 GMT

Allon Presents Peripheral Neuropathy Preclinical Efficacy Data For AL-309 (Marketwire via Yahoo! Finance)
TOKYO, JAPAN--(Marketwire - 02/23/10) - Allon Therapeutics Inc . (TSX: NPC - News ) today announced preclinical data demonstrating the potential of AL-309 , the Company's early-stage drug candidate. AL-309 is being investigated as a treatment for peripheral neuropathy, a debilitating and painful disorder of the peripheral nervous system afflicting millions of people for which there is no ...
Tue, 23 Feb 2010 14:00:00 GMT

For the Treatment of Diabetic Neuropathy, a Drug That Has Disease-Modifying Potential Would Earn Similar Patient Share ... (PR Newswire via Yahoo! Finance)
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of diabetic neuropathy, a drug that has disease-modifying potential would earn 40 percent patient share in the U.S., according to surveyed U.S. neurologists.
Mon, 22 Feb 2010 14:31:00 GMT

Neuropathy group meets Friday (Chico Enterprise-Record)
CHICO ? A pharmacist will discuss compounding medications during a meeting Friday of Chico Peripheral Neuropathy Support Group at Enloe Conference Center.
Tue, 16 Feb 2010 08:30:47 GMT

Page:  1